RMD Open (Oct 2023)

Sex-specific diagnostic efficacy of MRI in axial spondyloarthritis: challenging the ‘One Size Fits All’ notion

  • Denis Poddubnyy,
  • Torsten Diekhoff,
  • Sevtap Tugce Ulas,
  • Sarah Ohrndorf,
  • Iris Eshed,
  • Fabian Proft,
  • Mikhail Protopopov,
  • Judith Rademacher,
  • Juliane Greese,
  • Katharina Ziegeler,
  • Kay Geert A Hermann,
  • Valeria Rios,
  • Lisa C Adams

DOI
https://doi.org/10.1136/rmdopen-2023-003252
Journal volume & issue
Vol. 9, no. 4

Abstract

Read online

Objectives Sex-specific differences in the presentation of axial spondyloarthritis (axSpA) may contribute to a diagnostic delay in women. The aim of this study was to investigate the diagnostic performance of MRI findings comparing men and women.Methods Patients with back pain from six different prospective cohorts (n=1194) were screened for inclusion in this post hoc analysis. Two blinded readers scored the MRI data sets independently for the presence of ankylosis, erosion, sclerosis, fat metaplasia and bone marrow oedema. Χ2 tests were performed to compare lesion frequencies. Contingency tables were used to calculate markers for diagnostic performance, with clinical diagnosis as the standard of reference. The positive and negative likelihood ratios (LR+/LR–) were used to calculate the diagnostic OR (DOR) to assess the diagnostic performance.Results After application of exclusion criteria, 526 patients (379 axSpA (136 women and 243 men) and 147 controls with chronic low back pain) were included. No major sex-specific differences in the diagnostic performance were shown for bone marrow oedema (DOR m: 3.0; f: 3.9). Fat metaplasia showed a better diagnostic performance in men (DOR 37.9) than in women (DOR 5.0). Lower specificity was seen in women for erosions (77% vs 87%), sclerosis (44% vs 66%), fat metaplasia (87% vs 96%).Conclusion The diagnostic performance of structural MRI markers is substantially lower in female patients with axSpA; active inflammatory lesions show comparable performance in both sexes, while still overall inferior to structural markers. This leads to a comparably higher risk of false positive findings in women.